Artivion, Inc. AORT

Company Overview

Artivion, Inc. is a U.S.-based medical technology and cardiac surgery company focused on developing, manufacturing, and commercializing products used in aortic disease treatment, cardiac surgery, and tissue preservation. The company operates primarily within the cardiovascular medical device and implantable biologics industries, serving hospitals, cardiac surgeons, and specialty surgical centers globally. Its principal revenue drivers include aortic stent grafts, surgical sealants, mechanical heart valves, and implantable cardiac and vascular tissues. Artivion positions itself as a specialized provider in complex aortic repair and cardiac surgery markets, with an emphasis on physician-focused innovation and integrated procedural solutions.

The company was founded in 1984 as CryoLife, Inc., initially concentrating on the preservation and distribution of human tissues for cardiac and vascular procedures. Over time, the company expanded into medical devices through internal development and acquisitions, including aortic stent graft technologies and surgical adhesives. In 2022, CryoLife formally rebranded as Artivion, Inc. to reflect its broader focus on advanced cardiovascular therapies and innovation-driven surgical technologies.

Business Operations

Artivion generates revenue through the sale of medical devices, implantable tissues, preservation services, and related cardiovascular surgical products. Its operations are organized around several core product categories, including Aortic Stent Grafts, On-X Mechanical Heart Valves, BioGlue Surgical Adhesive, and implantable cardiac and vascular tissues. The company’s product portfolio includes technologies used in open surgical repair and minimally invasive endovascular procedures for aortic aneurysms and dissections. A significant portion of revenue is derived from products acquired through strategic transactions, including the acquisition of JOTEC GmbH, which expanded Artivion’s endovascular aortic repair platform in Europe and other international markets.

The company operates across both domestic and international markets, with commercial infrastructure in North America, Europe, Latin America, the Middle East, and Asia-Pacific. Artivion controls proprietary technologies related to tissue processing, polymer-based surgical sealants, and mechanical valve design. Its manufacturing and processing capabilities include tissue preservation facilities and specialized medical device production operations. The company also maintains physician training and clinical support programs to support adoption of its cardiovascular technologies.

Strategic Position & Investments

Artivion’s strategic direction centers on expanding its presence in the global aortic repair market, increasing adoption of minimally invasive therapies, and broadening its surgical device portfolio. A major component of this strategy has been investment in the AMDS Hybrid Prosthesis platform and the continued expansion of its aortic stent graft portfolio. The company has also prioritized clinical evidence generation and regulatory approvals to support market penetration in the United States and internationally.

The acquisition of JOTEC GmbH represented one of Artivion’s most significant investments, strengthening its position in complex aortic disease treatment and expanding access to hybrid and endovascular technologies. Artivion has also invested in research and development tied to next-generation cardiovascular implants and physician-driven product innovation. The company’s strategic emphasis remains concentrated on high-acuity cardiovascular procedures where specialized surgical expertise and differentiated technologies create competitive advantages.

Geographic Footprint

Artivion is headquartered in Kennesaw, Georgia, United States, and maintains operations across multiple global regions. The company has a substantial commercial presence in North America and Europe, with Europe serving as a particularly important market due to the integration of JOTEC GmbH and the company’s aortic stent graft operations. Artivion also sells products in parts of Asia-Pacific, Latin America, and the Middle East through direct sales organizations and distributor relationships.

Its international footprint includes manufacturing, tissue processing, regulatory, and sales support operations that enable the company to participate in both developed and emerging cardiovascular treatment markets. Artivion’s products are used by cardiac and vascular surgeons globally, particularly in centers specializing in complex aortic reconstruction and cardiovascular surgery.

Leadership & Governance

Artivion’s leadership team is focused on long-term expansion in cardiovascular surgery and aortic disease management, with strategic priorities centered on innovation, clinical adoption, and international growth. The company’s governance structure includes executive leadership with backgrounds in medical devices, cardiovascular technologies, and healthcare operations. Public filings and investor communications consistently emphasize disciplined portfolio expansion, physician collaboration, and operational scalability.

Key executives include:

• Pat Mackin – Chairman, President, and Chief Executive Officer
• D. Ashley Lee – Executive Vice President and Chief Financial Officer
• John A. Davis – Executive Vice President and Chief Operating Officer
• James P. Mackin – Executive Vice President, Corporate Development and General Counsel
• Jennifer Farrington – Senior Vice President, Human Resources

The company’s leadership philosophy emphasizes specialized cardiovascular innovation, surgeon-focused product development, and growth through a combination of internal research and targeted acquisitions.